Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IB includes: T2, N0, M0, B0,1. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

Stage II includes: IIA (T1,2, N1,2, M0, B0,1); IIB (T3, N0-2, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IIA includes:  T1-2, N1,2, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IIB includes: T3, N0-2, M0, B0,1. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage III includes: (T4, N0-2, M0, B0,1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IIIA includes: T4, N0-2, M0, B0. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). (AJCC 8th ed.)


Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IIIB includes: T4, N0-2, M0, B1. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IV includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2); IVB (T1-4, N0-3, M1, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement.  M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IVA1 includes: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IVA2 includes: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8

Stage IVB includes: T1-4, N0-3, M1, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


RISS Stage I Multiple Myeloma

Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)


RISS Stage II Multiple Myeloma

Not stage I or III. (from AJCC 8th Ed.)


acute biphenotypic leukemia in relapse

The reemergence of acute biphenotypic leukemia after a period of remission.


acute undifferentiated leukemia in relapse

The reemergence of acute undifferentiated leukemia after a period of remission.


Malignant Bowel Obstruction

Obstruction of the bowel by an advanced malignant tumor. It is a complication especially in patients with an advanced abdominal malignant tumor.


Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.


Blasts More than 5 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


t(11;14) Positive

A cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample.


Waldenstrom macroglobulinemia that does not respond to treatment.


Refractory Pancreatic Carcinoma

Pancreatic carcinoma that does not respond to treatment.


Acute lymphoblastic leukemia recurrent

The reemergence of acute lymphoblastic leukemia after a period of remission.


Recurrent B Acute Lymphoblastic Leukemia

The reemergence of B acute lymphoblastic leukemia after a period of remission.


Refractory B Acute Lymphoblastic Leukemia

B-acute lymphoblastic leukemia that does not respond to treatment.


Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation

A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.


Recurrent Malignant Glioma

The reemergence of malignant glioma after a period of remission.


Recurrent Rhabdoid Tumor

The reemergence of rhabdoid tumor after a period of remission.


Refractory Peripheral Primitive Neuroectodermal Tumor

Peripheral primitive neuroectodermal tumor that does not respond to treatment.


Refractory Rhabdomyosarcoma

Rhabdomyosarcoma that does not respond to treatment.


Refractory Ewing Sarcoma

Ewing sarcoma that does not respond to treatment.


Refractory Hepatoblastoma

Hepatoblastoma that does not respond to treatment.


Refractory Malignant Glioma

Malignant glioma that does not respond to treatment.


Refractory Medulloblastoma

Medulloblastoma that does not respond to treatment.


Refractory Osteosarcoma

Osteosarcoma that does not respond to treatment.


Refractory Rhabdoid Tumor

Rhabdoid tumor that does not respond to treatment.


Metastatic Microsatellite Stable Colorectal Carcinoma

A microsatellite stable carcinoma that arises from the colon or rectum and has metastasized to other anatomic sites.


Advanced Microsatellite Stable Colorectal Carcinoma

A microsatellite stable carcinoma that arises from the colon or rectum and has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Bile Duct Carcinoma

A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites.


Advanced Bile Duct Carcinoma

A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has spread extensively to other anatomic sites or is no longer responding to treatment.


KRAS Gene Mutation Negative

A genetic finding indicating that KRAS gene mutations have not been detected in a sample.


Refractory Alveolar Rhabdomyosarcoma

Alveolar rhabdomyosarcoma that does not respond to treatment.


Recurrent Alveolar Rhabdomyosarcoma

The reemergence of alveolar rhabdomyosarcoma after a period of remission.


Refractory Thyroid Gland Carcinoma

Thyroid gland carcinoma that does not respond to treatment.


Skin squamous cell carcinoma recurrent

The reemergence of squamous cell carcinoma of the skin after a period of remission.


Skin squamous cell carcinoma metastatic

Squamous cell carcinoma of the skin which has spread to other anatomic sites.


Inoperable Disease

Disease state in which the surgical removal of a tumor is not feasible or useful.


Marginal zone lymphoma refractory

Marginal zone lymphoma which does not respond to treatment.


Blasts Under 15 Percent of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Blasts Under 15 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


Blasts Under 30 Percent of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Testosterone Deficiency, CTCAE

A disorder characterized by low testosterone.


Cytomegalovirus Infection Reactivation, CTCAE

A disorder characterized by the reactivation of cytomegalovirus (CMV).


Hepatitis B Reactivation, CTCAE

A disorder characterized by the reactivation of hepatitis B virus.


Rotator Cuff Injury, CTCAE

A disorder characterized by an injury of the rotator cuff.


Death Neonatal, CTCAE

Newborn death occurring during the first 28 days after birth.


Fall, CTCAE

A finding of sudden movement downward, usually resulting in injury.


Injection Site Reaction, CTCAE

A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.


Blasts More Than 5 Percent of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.


Lymphoblasts 20 Percent or More of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of lymphoid origin.


Blasts 20-30 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


Refractory Glioblastoma

A glioblastoma that is resistant to treatment.


Locally Advanced Angiosarcoma

An angiosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Epithelioid Hemangioendothelioma

An epithelioid hemangioendothelioma that has spread from its original site of growth to nearby tissues or lymph nodes.


An epithelioid hemangioendothelioma that has spread from its original site of growth to another anatomic site.


Metastatic Genitourinary System Carcinoma

A carcinoma that arises from the genitourinary system and has metastasized to other anatomic sites.


Metastatic Neuroendocrine Tumor

A neuroendocrine tumor that has spread from its original site of growth to another anatomic site.


developmental and epileptic encephalopathy, 2

Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the CDKL5 gene.


BRAF Fusion Positive

An indication that BRAF fusion expression has been detected in a sample.


Refractory Glioma

Glioma that does not respond to treatment.


Refractory Ependymoma

Ependymoma that does not respond to treatment.


Steroid Refractory Graft Versus Host Disease

Graft versus host disease that does not respond to steroid treatment.


Platinum-Resistant Disease

A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms "platinum-resistant" and "platinum-refractory" are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.


Platinum-Resistant Ovarian Carcinoma

Ovarian carcinoma that progresses between one and six months of completing platinum therapy.


Recurrent Lymphoproliferative Disorder

The reemergence of a lymphoproliferative disorder after a period of remission.


Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

An oropharyngeal squamous cell carcinoma which is negative for p16INK4a by immunohistochemistry. This negative immunohistochemistry result does not exclude human papillomavirus infection.


Ibrutinib Resistance

A finding indicating that chronic lymphocytic leukemia does not respond to treatment with Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib.


Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Central Nervous System B-Cell Non-Hodgkin Lymphoma

A B-cell non-Hodgkin lymphoma that arises from the brain, meninges, or spinal cord.


Refractory Breast Carcinoma

Breast carcinoma that does not respond to treatment.


Refractory Colorectal Carcinoma

Colorectal carcinoma that does not respond to treatment.


Refractory Melanoma

Melanoma that does not respond to treatment.


Refractory Gastric Carcinoma

Gastric carcinoma that does not respond to treatment.


BRCA-Associated Ovarian Carcinoma

Ovarian carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Recurrent WHO Grade 2 Glioma

The reemergence of WHO grade 2 glioma after a period of remission.


Recurrent WHO Grade 3 Glioma

The reemergence of a WHO grade III glioma after a period of remission.


Recurrent Craniopharyngioma

The reemergence of a craniopharyngioma after a period of remission.


FLT3 Gene Mutation Negative

A genetic finding indicating that FLT3 gene mutations have not been detected in a sample.


BRAF Gene Mutation Negative

A genetic finding indicating that BRAF gene mutations have not been detected in a sample.


NRAS Gene Mutation Negative

A genetic finding indicating that NRAS gene mutations have not been detected in a sample.


Unresectable Carcinoma

Carcinoma that is not amenable to surgical resection.


Unresectable Thymic Carcinoma

A thymic carcinoma that is not amenable to surgical resection.


Locally Advanced Thymic Carcinoma

A thymic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Recurrent Thymic Carcinoma

Thymic carcinoma that has recurred after a period of remission.


Metastatic thymic carcinoma

A carcinoma that arises from the thymus and has spread from its original site of growth to another anatomic site.


Mycosis fungoides/Sezary syndrome refractory

Mycosis fungoides and Sezary syndrome that is resistant to treatment.


Locally Advanced Carcinoma

A carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Refractory Head and Neck Squamous Cell Carcinoma

A head and neck squamous cell carcinoma that does not respond to treatment.


Squamous cell carcinoma of head and neck metastatic

A head and neck squamous cell carcinoma which has spread from the original site of growth to another anatomic site.


Refractory Indolent Adult Non-Hodgkin Lymphoma

Indolent adult non-Hodgkin lymphoma that is resistant to treatment.


Recurrent Grade 3a Follicular Lymphoma

The reemergence of grade 3a follicular lymphoma after a period of remission.


Unresectable Cutaneous Melanoma

A skin melanoma that is not amenable to surgical resection.


Refractory Leiomyosarcoma

Leiomyosarcoma that does not respond to treatment.


Refractory Undifferentiated Pleomorphic Sarcoma

Undifferentiated pleomorphic sarcoma that does not respond to treatment.


Refractory Synovial Sarcoma

Synovial sarcoma that does not respond to treatment.


Refractory Myxoid Liposarcoma

Myxoid liposarcoma that does not respond to treatment.


Myxoid liposarcoma metastatic

Myxoid liposarcoma that has spread to other anatomic sites.


Refractory Round Cell Liposarcoma

Round cell liposarcoma that does not respond to treatment.


Metastatic Round Cell Liposarcoma

Round cell liposarcoma that has spread to other anatomic sites.


Refractory Sarcoma

A sarcoma that does not respond to treatment.


Recurrent Sarcoma

The reemergence of sarcoma after a period of remission.


Unresectable Sarcoma

A sarcoma which is not amenable to surgical resection.


Refractory Myelodysplastic Syndrome

Myelodysplastic syndrome that does not respond to treatment.


Refractory Oropharyngeal Squamous Cell Carcinoma

Oropharyngeal squamous cell carcinoma that does not respond to treatment.


Recurrent Paranasal Sinus Squamous Cell Carcinoma

The reemergence of paranasal sinus squamous cell carcinoma after a period of remission.


Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes

Molecular subtyping of diffuse large B-cell lymphomas (DLBCL) based on structural genomic abnormalities and gene expression data obtained from biopsy samples. The molecular analysis revealed four subtypes of DLBCL (MCD, BN2, N1, and EZB) which have distinct genotypic, epigenetic, and clinical characteristics. (NEJM 2018; 378: 1396-407)


Moderate Hepatic Insufficiency

Findings indicating moderate impairment of liver function.


Recurrent Mixed Phenotype Acute Leukemia

The reemergence of mixed phenotype acute leukemia after a period of remission.


Leukemia recurrent

The reemergence of leukemia after a period of remission.


Refractory Leukemia

Leukemia that is resistant to treatment.


Recurrent Acute Myeloid Leukemia

The reemergence of acute myeloid leukemia after a period of remission.


Recurrent Acute Leukemia

The reemergence of acute leukemia after a period of remission.


Refractory Mixed Phenotype Acute Leukemia

Mixed phenotype acute leukemia that does not respond to treatment.


Refractory Acute Leukemia

Acute leukemia that does not respond to treatment.


Intrahepatic cholangiocarcinoma that is not amenable to surgical removal.


Refractory Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma that is resistant to treatment.


Advanced Urothelial Carcinoma

Urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Melanoma

Melanoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic Uveal Melanoma

Uveal melanoma that has spread from its primary site to another anatomic site.


Advanced Uveal Melanoma

Uveal melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Unresectable Melanoma

Melanoma which is not amenable to surgical resection.


Castration-Naive Prostate Carcinoma

Advanced prostatic carcinoma which was not previously treated with androgen-deprivation therapy.


Acute pulmonary embolism

An acute embolism to the pulmonary vasculature.


Thoracic Esophagus Adenocarcinoma

An adenocarcinoma that arises from the thoracic esophagus.


Cervical Esophagus Adenocarcinoma

An adenocarcinoma that arises from the cervical esophagus.


Recurrent Chronic Myelomonocytic Leukemia

The reemergence of chronic myelomonocytic leukemia after a period of remission.


Refractory Chronic Myelomonocytic Leukemia

Chronic myelomonocytic leukemia that is resistant to treatment.


Refractory Ovarian Carcinoma

Ovarian carcinoma that is resistant to treatment.


Refractory Endometrial Carcinoma

Endometrial carcinoma that is resistant to treatment


Recurrent Endometrial Cancer

The reemergence of endometrial carcinoma after a period of remission.


Recurrent Ovarian Endometrioid Adenocarcinoma

The reemergence of ovarian endometrioid adenocarcinoma after a period of remission.


Refractory Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that is resistant to treatment.


Recurrent Endometrial Endometrioid Adenocarcinoma

The reemergence of endometrial endometrioid adenocarcinoma after a period of remission.


Refractory Endometrial Endometrioid Adenocarcinoma

Endometrial endometrioid adenocarcinoma that is resistant to treatment.


Uveal Melanoma Metastatic in the Liver

A melanoma that originates from melanocytes of the uveal tract and has spread to the liver.


Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma

The reemergence of monomorphic epitheliotropic intestinal T-cell lymphoma after a period of remission.


Recurrent T-Cell Prolymphocytic Leukemia

The reemergence of T-cell prolymphocytic leukemia after a period of remission.


Advanced Oropharyngeal Squamous Cell Carcinoma

A squamous cell carcinoma of the oropharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Squamous Cell Carcinoma of the Oropharynx

A squamous cell carcinoma of the oropharynx which has spread from the original site of growth to another anatomic site.


Advanced Oral Cavity Squamous Cell Carcinoma

A squamous cell carcinoma of the oral cavity that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Oral Cavity Squamous Cell Carcinoma

A squamous cell carcinoma of the oral cavity which has spread from the original site of growth to another anatomic site.


Metastatic Squamous Cell Carcinoma of the Nasopharynx

A squamous cell carcinoma of the nasopharynx which has spread from the original site of growth to another anatomic site.


Advanced Hypopharyngeal Squamous Cell Carcinoma

A squamous cell carcinoma of the hypopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Laryngeal Squamous Cell Carcinoma

A squamous cell carcinoma of the larynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


Squamous cell carcinoma of the hypopharynx stage IV

A squamous cell carcinoma of the hypopharynx that has spread from the original site of growth to another anatomic site.


Metastatic Squamous Cell Carcinoma of the Larynx

A squamous cell carcinoma of the larynx that has spread from the original site of growth to another anatomic site.


High Risk Neuroblastoma

Neuroblastoma usually presenting with metastatic disease and MYCN gene amplifications.


Refractory Bladder Carcinoma

Bladder carcinoma that does not respond to treatment.


Refractory Urothelial Carcinoma

Urothelial carcinoma that does not respond to treatment.


Platinum-Resistant Urothelial Carcinoma

Urothelial carcinoma that is resistant to platinum therapy.


HHV-8-Associated Multicentric Castleman Disease

Multicentric Castleman disease associated with HHV8 infection.


Blasts 20-30 Percent of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Blasts More than 10 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that more than 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


Blasts More than 20 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


Blasts More than 20 Percent of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Refractory T Acute Lymphoblastic Leukemia

T-acute lymphoblastic leukemia that does not respond to treatment.


Metastatic Urethral Urothelial Carcinoma

A urethral urothelial carcinoma that has spread to another anatomical site.


Metastatic Bladder Urothelial Carcinoma

Bladder urothelial carcinoma that has spread to another anatomical site.


Metastatic Renal Pelvis Urothelial Carcinoma

Renal pelvis urothelial carcinoma that has spread to another anatomical site.


Urothelial carcinoma ureter metastatic

Ureter urothelial carcinoma that has spread to another anatomical site.


Urothelial carcinoma ureter recurrent

The reemergence of ureter urothelial carcinoma after a period of remission.


Recurrent Renal Pelvis Urothelial Carcinoma

The reemergence of renal pelvis urothelial carcinoma after a period of remission.


Unresectable Urothelial Carcinoma

Urothelial carcinoma that is not amenable to surgical resection.


Refractory Malignant Bone Neoplasm

Malignant bone neoplasm that is resistant to treatment.


Recurrent Malignant Female Reproductive System Neoplasm

The reemergence of a malignant female reproductive system neoplasm after a period of remission.


Refractory Malignant Female Reproductive System Neoplasm

Malignant female reproductive system neoplasm that is resistant to treatment.


Recurrent Malignant Neoplasm of Multiple Primary Sites

Reemergence of a malignant neoplasm of multiple primary sites after a period of remission.


Refractory Malignant Neoplasm of Multiple Primary Sites

Malignant neoplasm of multiple primary sites that is resistant to treatment.


Refractory Malignant Oral Neoplasm

Lip or oral cavity malignant neoplasm that is resistant to treatment.


Recurrent Malignant Pharyngeal Neoplasm

Reemergence of a malignant pharyngeal neoplasm after a period of remission.


Refractory Malignant Pharyngeal Neoplasm

Malignant pharyngeal neoplasm that is resistant to treatment.


Recurrent Malignant Male Reproductive System Neoplasm

The reemergence of a malignant male reproductive system neoplasm after a period of remission.


Refractory Malignant Male Reproductive System Neoplasm

Malignant male reproductive system neoplasm that is resistant to treatment.


Refractory Malignant Mesothelioma

Malignant mesothelioma that is resistant to treatment.


Recurrent Malignant Soft Tissue Neoplasm

Reemergence of a malignant soft tissue neoplasm after a period of remission.


Refractory Malignant Soft Tissue Neoplasm

Malignant soft tissue neoplasm that is resistant to treatment.


Recurrent Malignant Thyroid Gland Neoplasm

The reemergence of malignant thyroid gland neoplasm after a period of remission.


Refractory Malignant Thyroid Gland Neoplasm

Malignant thyroid gland neoplasm that is resistant to treatment.


Recurrent Malignant Endocrine Neoplasm

Reemergence of a malignant endocrine neoplasm after a period of remission.


Refractory Malignant Endocrine Neoplasm

Malignant endocrine neoplasm that is resistant to treatment.


Recurrent Malignant Urinary System Neoplasm

Reemergence of a malignant urinary system neoplasm after a period of remission.


Refractory Malignant Urinary System Neoplasm

Malignant urinary system neoplasm that is resistant to treatment.


Refractory Cutaneous Melanoma

Melanoma of the skin that is resistant to treatment.


Recurrent Malignant Skin Neoplasm

Reemergence of a malignant skin neoplasm after a period of remission.


Refractory Malignant Skin Neoplasm

Malignant skin neoplasm that is resistant to treatment.


Prostate Adenocarcinoma without Neuroendocrine Differentiation

A prostate adenocarcinoma characterized by the absence of focal or diffuse neuroendocrine differentiation.


IgM monoclonal gammopathy of uncertain significance

Monoclonal gammopathy of undetermined significance defined by a serum IgM paraprotein concentration less than 30g/L; bone marrow lymphoplasmacytic infiltration of less than 10%; and no evidence of anemia, constitutional symptoms, hyperviscocity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the underlying lymphoproliferative disorder. It is a precursor condition that may progress to lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia, other B-cell neoplasms, or primary amyloidosis. Progression to plasma cell myeloma occurs rarely, if at all. (WHO 2017)


Muscle Invasive Bladder Carcinoma

A carcinoma that arises from the bladder mucosa and invades the muscle of the bladder wall.


Metastatic Gastroesophageal Junction Adenocarcinoma

Gastroesophageal junction adenocarcinoma which has spread from its original site of growth to another anatomic site.


Unresectable Gastroesophageal Junction Adenocarcinoma

Gastroesophageal junction adenocarcinoma that is not amenable to surgical resection.


Recurrent Myxoid Liposarcoma

The reemergence of myxoid liposarcoma after a period of remission.


Unresectable Adrenal Cortical Carcinoma

Adrenal cortical carcinoma that is not amenable to surgical resection.


Refractory Lung Small Cell Carcinoma

Small cell lung carcinoma that does not respond to treatment.


Recurrent Dedifferentiated Liposarcoma

The reemergence of dedifferentiated liposarcoma after a period of remission.


Refractory Dedifferentiated Liposarcoma

Dedifferentiated liposarcoma that does not respond to treatment.


Refractory Liposarcoma

Liposarcoma that does not respond to treatment.


Metastatic Renal Cell Carcinoma

Renal cell carcinoma that has spread from the kidney to other anatomic sites.


Metastatic malignant neoplasm to viscera

A malignant neoplasm which has spread from its original site of growth to any visceral site.


Dedifferentiated liposarcoma that is not amenable to surgical resection.


Resectable Carcinoma

Carcinoma that is amenable to surgical resection.


Resectable Sarcoma

Sarcoma that is amenable to surgical resection.


Resectable Liposarcoma

Liposarcoma that is amenable to surgical resection.


Resectable Dedifferentiated Liposarcoma

Dedifferentiated liposarcoma that is amenable to surgical resection.


Unresectable Undifferentiated Pleomorphic Sarcoma

Undifferentiated pleomorphic sarcoma that is not amenable to surgical resection.


Resectable Undifferentiated Pleomorphic Sarcoma

Undifferentiated pleomorphic sarcoma that is amenable to surgical resection.


FLT3 Internal Tandem Duplication Positive

An indication that internal tandem duplication within the FLT3 gene has been detected in a sample.


SMARCB1 Negative

An indication that expression of SMARCB1 has not been detected in a sample.


COL6A3 Positive

An indication that expression of COL6A3 has been detected in a sample.


Metastatic Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumor which has spread from its original site of growth to another anatomic site.


Locally Advanced Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumor that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Malignant Gastrointestinal Stromal Tumor

Malignant gastrointestinal stromal tumor that is not amenable to surgical resection.


Human Immunodeficiency Virus Positive

A laboratory test result indicating the presence of the human immunodeficiency virus (HIV) in a sample.


Refractory Metastatic Digestive System Carcinoma

A digestive system carcinoma that has metastasized to another anatomic site and is resistant to treatment.


Hematologic Neoplasm with Germline GATA2 Mutation

Myelodysplastic syndromes/acute myeloid leukemias associated with germline GATA2 mutation.


Transformed Non-Hodgkin Lymphoma

Histologic transformation of a usually indolent non-Hodgkin lymphoma to an aggressive non-Hodgkin lymphoma.


Recurrent Burkitt Leukemia

The reemergence of Burkitt leukemia after a period of remission.


Refractory Burkitt Leukemia

Burkitt leukemia resistant to treatment.


Refractory Lymphoblastic Lymphoma

Lymphoblastic lymphoma that is resistant to treatment.


Refractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

High-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements that is resistant to treatment.


Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

The reemergence of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements after a period of remission.


Pelvic Rhabdomyosarcoma

Rhabdomyosarcoma involving the organs and structures in the pelvis.


Abdominal Rhabdomyosarcoma

Rhabdomyosarcoma involving the organs and structures in the abdomen.


Locally Advanced Pancreatic Ductal Adenocarcinoma

A pancreatic ductal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma amenable to surgical resection.


Distal Esophagus Adenocarcinoma

An adenocarcinoma arising from the lower third of the esophagus. The vast majority of esophageal adenocarcinomas involve the lower third of the esophagus.


Refractory Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that is resistant to treatment.


Refractory Fallopian Tube Carcinoma

Fallopian tube carcinoma that is resistant to treatment.


Refractory Female Reproductive System Carcinoma

Female reproductive system carcinoma that is resistant to treatment.


Metastatic Unresectable Sarcoma

A metastatic sarcoma that is not amenable to surgical resection.


Metastatic sarcoma

A sarcoma that has spread from its original site of growth to another anatomic site.


Recurrent Malignant Head and Neck Neoplasm

The reemergence of a malignant head and neck neoplasm after a period of remission.


Chronic Hemolysis

Persisting and longstanding disruption of erythrocyte membrane integrity and the resulting release of hemoglobin.


Locally Advanced Soft Tissue Sarcoma

Soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Soft Tissue Sarcoma

Soft tissue sarcoma that is not amenable to surgical resection.


Locally Advanced Bone Sarcoma

Bone sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Sarcoma

Sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Bone Sarcoma

Bone sarcoma that is not amenable to surgical resection.


Metastatic Bone Sarcoma

Bone sarcoma that has spread from the original site of growth to another anatomic site.


Unresectable Synovial Sarcoma

Synovial sarcoma that is not amenable to surgical resection.


Metastatic Pancreatic Neuroendocrine Carcinoma

Pancreatic neuroendocrine carcinoma that has spread from the original site of growth to another anatomic site.


Unresectable Pancreatic Neuroendocrine Carcinoma

Pancreatic neuroendocrine carcinoma that is not amenable to surgical resection.


Unresectable Neuroendocrine Tumor G1

Neuroendocrine tumor grade 1 that is not amenable to surgical resection.


Refractory Lung Non-Small Cell Carcinoma

Non-small cell lung carcinoma that does not respond to treatment.


Resectable Soft Tissue Sarcoma

Soft tissue sarcoma that is amenable to surgical resection.


Recurrent Hepatosplenic T-Cell Lymphoma

The reemergence of hepatosplenic T-cell lymphoma after a period of remission.


Refractory Hepatosplenic T-Cell Lymphoma

Hepatosplenic T-cell lymphoma that is resistant to treatment.


BRAF V600E Negative

An indication that expression of the BRAF V600E mutation has not been detected in a sample.


Advanced Melanoma

Melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced renal cell carcinoma

Renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Carcinoma

Carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Lymphoma

Lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Recurrent Mediastinal Lymphoma

The reemergence of a mediastinal lymphoma after a period of remission.


Refractory Mediastinal Lymphoma

Mediastinal lymphoma that is resistant to treatment.


Locally Advanced Skin Squamous Cell Carcinoma

A squamous cell carcinoma of the skin that has spread from its original site of growth to nearby tissues or lymph nodes.


Advanced Synovial Sarcoma

A synovial sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Sarcoma

A sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Advanced Lung Non-Small Cell Squamous Carcinoma

Non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Lung Carcinoma

A carcinoma that arises from the lung and has metastasized to another anatomic site.


Advanced Lung Carcinoma

A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Lung Carcinoma

A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Head and Neck Carcinoma

A head and neck carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Elevated WT1

A finding indicating elevated concentrations of WT1 in a sample.


Metastatic Breast Carcinoma

A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

A malignant small round cell tumor with or without neural differentiation that is resistant to treatment.


Recurrent Severe Aplastic Anemia

The reemergence of severe aplastic anemia after a period of remission.


Refractory Severe Aplastic Anemia

Severe aplastic anemia that is resistant to treatment.


Metastatic Unresectable Gastric Adenocarcinoma

A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.


Metastatic gastric adenocarcinoma

A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Gastric Carcinoma

A gastric carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Chordoma

A chordoma that has spread from its original site of growth to other anatomic sites.


Locally Advanced Chordoma

A chordoma that has spread from its original site of growth to nearby tissues.


Unresectable Chordoma

A chordoma which is not amenable to surgical resection.


Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

The reemergence of EBV-positive diffuse large B-cell lymphoma, not otherwise specified after a period of remission.


Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

EBV-positive diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.


Castration-Sensitive Prostate Carcinoma

Metastatic prostatic carcinoma which is sensitive to androgen-deprivation therapy.


Recurrent Ovarian Carcinosarcoma

The reemergence of ovarian carcinosarcoma after a period of remission.


Metastatic Triple-Negative Breast Carcinoma

A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Refractory Colon Carcinoma

Colon carcinoma that is resistant to treatment.


Refractory Liver Carcinoma

Liver carcinoma that is resistant to treatment.


Refractory Bile Duct Carcinoma

Bile duct carcinoma that is resistant to treatment.


Recurrent Gastroesophageal Junction Adenocarcinoma

The reemergence of gastroesophageal junction adenocarcinoma after a period of remission.


Metastatic Cervical Carcinoma

A carcinoma of the cervix that has spread to another anatomic site.


Metastatic Cervical Adenocarcinoma

A cervical adenocarcinoma that has spread to another anatomic site.


Locally Advanced Unresectable Soft Tissue Sarcoma

A soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Recurrent Clear Cell Renal Cell Carcinoma

The reemergence of clear cell renal cell carcinoma after a period of remission.


Recurrent Ovarian Adenocarcinoma

The reemergence of ovarian adenocarcinoma after a period of remission.


Recurrent Ovarian Serous Adenocarcinoma

The reemergence of ovarian serous adenocarcinoma after a period of remission.


Recurrent Ovarian Mucinous Adenocarcinoma

The reemergence of ovarian mucinous adenocarcinoma after a period of remission.


Recurrent Ovarian Clear Cell Adenocarcinoma

The reemergence of ovarian clear cell adenocarcinoma after a period of remission.


Recurrent Thyroid Gland Papillary Carcinoma

The reemergence of thyroid gland papillary carcinoma after a period of remission.


Recurrent Thyroid Gland Follicular Carcinoma

The reemergence of thyroid gland follicular carcinoma after a period of remission.


Recurrent Thyroid Gland Medullary Carcinoma

The reemergence of thyroid gland medullary carcinoma after a period of remission.


Recurrent Ovarian Transitional Cell Carcinoma

The reemergence of ovarian transitional cell carcinoma after a period of remission.


Recurrent Primary Malignant Central Nervous System Neoplasm

The reemergence of a primary malignant central nervous system neoplasm after a period of remission.


Recurrent Malignant Brain Neoplasm

The reemergence of a malignant brain neoplasm after a period of remission.


Refractory Primary Malignant Central Nervous System Neoplasm

A primary malignant central nervous system neoplasm that is resistant to treatment.


Refractory Malignant Brain Neoplasm

A malignant brain neoplasm that is resistant to treatment.


Refractory WHO Grade 3 Glioma

A WHO grade 3 glioma that is resistant to treatment.


Metastatic liver carcinoma

A carcinoma that arises from the liver and has spread to another anatomic site.


Metastatic hepatocellular carcinoma

A hepatocellular carcinoma that has spread to another anatomic site.


Blasts 20 Percent or Less of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


PTEN Positive

An indication that PTEN expression has been detected in a sample.


Testosterone Greater than 150 ng/dL

A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 150 ng/dL.


Postmenopausal

After menopause.


Unresectable Gastric Adenocarcinoma

A gastric adenocarcinoma that is not amenable to surgical resection.


Vulvovaginal Atrophy

A condition associated with decreased estrogen production, characterized by dryness, inflammation, and itching of the vulva and vaginal tissues. It may also be associated with dysuria and dyspareunia.


Locally Advanced Squamous Cell Carcinoma

A squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Sinonasal Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the nasal cavity and/or paranasal sinuses and has spread from its original site of growth to nearby tissues or lymph nodes.


Sinonasal Poorly Differentiated Carcinoma

A poorly differentiated carcinoma that arises from the nasal cavity and/or paranasal sinuses.


Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified

The reemergence of peripheral T-cell lymphoma, not otherwise specified after a period of remission.


MGMT-Methylated Glioblastoma

A glioblastoma characterized by the presence of DNA methylation in the promoter region of the MGMT gene. It is associated with improved survival.


Resectable Malignant Mesothelioma

Malignant mesothelioma that is amenable to surgical resection.


Melanoma of Unknown Primary

A melanoma which has metastasized from an unknown primary anatomic site.


Unresectable Renal Cell Carcinoma

A renal cell carcinoma that is not amenable to surgical resection.


Advanced Neuroendocrine Tumor

A neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


Adenocarcinoma gastric recurrent

The reemergence of gastric adenocarcinoma after a period of remission.


Vital Signs

Vital signs (such as height, weight, and blood pressure) directly measure an individual's current state of attributes.


Premenopausal

Prior to menopause.


Estrogen Receptor Positive

An indication that estrogen receptor alpha expression has been detected in a sample.


Estrogen Receptor Negative

The absence of detectable estrogen receptor alpha in a tissue sample.


Neonatal Hypotension, AE

An adverse event in a newborn characterized by abnormally low blood pressure, which is usually symptomatic.


Progesterone Receptor Positive

An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.


Progesterone Receptor Negative

An indication that progesterone receptor (PRG; PR) expression has not been detected in a sample.


Status epilepticus without prominent motor symptoms

There is inconclusive evidence to precisely define the duration of the seizure; however, based on current evidence an operational threshold of 10 minutes is appropriate as beyond this a seizure is likely to be more prolonged. The individual may or may not be aware or in coma.


Proliferative retinopathy

Retinopathy characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.


Sarcoma of the Extremity

A sarcoma that arises from the soft tissues or bones of the upper or lower extremity.


Locally Advanced Unresectable Renal Cell Carcinoma

A renal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Pancreatic adenocarcinoma recurrent

The reemergence of pancreatic adenocarcinoma after a period of remission.


Locally Advanced Unresectable Pancreatic Adenocarcinoma

A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Suprasellar Germinoma

A germinoma that arises from the suprasellar region.


Recurrent Endometrial Clear Cell Adenocarcinoma

The reemergence of endometrial clear cell adenocarcinoma after a period of remission.


Recurrent Endometrial Undifferentiated Carcinoma

The reemergence of endometrial undifferentiated carcinoma after a period of remission.


Recurrent Uterine Corpus Carcinosarcoma

The reemergence of uterine corpus carcinosarcoma after a period of remission.


Recurrent Endometrial Mixed Cell Adenocarcinoma

The reemergence of endometrial mixed cell adenocarcinoma after a period of remission.


Well Differentiated Neuroendocrine Lesion

A neoplastic lesion with neuroendocrine differentiation and well differentiated histological features.


Neuroendocrine carcinoma, metastatic

A neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


Advanced Neuroendocrine Carcinoma

A neuroendocrine carcinoma that has metastasized from its original site of growth to distal anatomic sites or is no longer responding to treatment.


Locally Advanced Unresectable Gastric Adenocarcinoma

A gastric adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Recurrent Desmoid Fibromatosis

Desmoid fibromatosis that has recurred after a period of remission.


Unresectable Desmoid Fibromatosis

Desmoid fibromatosis that is not amenable to surgical resection.


Unresectable Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that is not amenable to surgical resection.


Metastatic Lung Adenocarcinoma

Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.


Waldenstrom macroglobulinemia with serum IgM monoclonal protein equal or more than 3 g/dL and/or at least 10% bone marrow lymphoplasmacytic infiltration but no evidence of constitutional symptoms, symptomatic anemia, or hyperviscosity. (Blood 2008, 112:2709)


Metastatic Malignant Neoplasm in the Thoracic Cavity

A malignant neoplasm that has spread to the thoracic cavity from another anatomic site.


Locally Advanced Pancreatic Neuroendocrine Carcinoma

A pancreatic neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Digestive System Neuroendocrine Carcinoma

A neuroendocrine carcinoma that arises from any part of the digestive system and has spread to nearby tissues or lymph nodes.


Unresectable Digestive System Neuroendocrine Carcinoma

A neuroendocrine carcinoma that arises from any part of the digestive system and is not amenable to surgical resection.


Metastatic Digestive System Neuroendocrine Carcinoma

A neuroendocrine carcinoma that arises from any part of the digestive system and has metastasized to another anatomic site.


Refractory Digestive System Neuroendocrine Carcinoma

A neuroendocrine carcinoma that arises from any part of the digestive system and does not respond to treatment.


Recurrent Chordoma

The reemergence of chordoma after a period of remission.


Refractory Visual Pathway Glioma

Visual pathway glioma that is resistant to treatment.


Recurrent Neurofibromatosis Type 1

The reemergence of neurofibromatosis type 1 after a period of remission.


Refractory Neurofibromatosis Type 1

Neurofibromatosis type 1 that is resistant to treatment.


Refractory Malignant Peripheral Nerve Sheath Tumor

Malignant peripheral nerve sheath tumor that is resistant to treatment.


MTAP Negative

An indication that MTAP expression or activity has not been detected in a sample.


Bladder cancer stage IV

A carcinoma that arises from the bladder and has metastasized to another anatomic site.


Metastatic Fallopian Tube Carcinoma

A carcinoma that arises from the fallopian tube and has metastasized to another anatomic site.


Stage IV Ovarian Carcinoma

A carcinoma that arises from the ovary and has metastasized to another anatomic site.


Metastatic Vaginal Carcinoma

A carcinoma that arises from the vagina and has metastasized to another anatomic site.


Metastatic Vulvar Carcinoma

A carcinoma that arises from the vulva and has metastasized to another anatomic site.


Metastatic Endometrial Carcinoma

A carcinoma that arises from the endometrium and has metastasized to another anatomic site.


stage IV pancreatic cancer

A carcinoma that arises from the pancreas and has metastasized to another anatomic site.


Stage IV adult soft tissue sarcoma

A sarcoma that arises from the soft tissues during adulthood and has spread from the original site of growth to another anatomic site.


Metastatic Cutaneous Melanoma

A melanoma that arises from the skin and has metastasized to another anatomic site.


Metastatic Esophageal Carcinoma

A carcinoma that arises from the esophagus and has metastasized to another anatomic site.


Esophageal adenocarcinoma stage IV

An adenocarcinoma that arises from the esophagus and has metastasized to another anatomic site.


Metastatic Esophageal Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the esophagus and has metastasized to another anatomic site.


Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma

A keratinizing squamous cell carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.


Metastatic Nasopharyngeal Undifferentiated Carcinoma

An undifferentiated carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.


Stage IV Nasopharyngeal Carcinoma

A carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.


Metastatic Oropharyngeal Carcinoma

A carcinoma that arises from the oropharynx and has metastasized to another anatomic site.


High Grade Dysplasia

A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.


Metastatic Lip and Oral Cavity Carcinoma

A carcinoma that arises from the lip and/or oral cavity and has metastasized to another anatomic site.


Metastatic Lung Non-Small Cell Carcinoma

A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Metastatic Lung Small Cell Carcinoma

A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Metastatic Colorectal Carcinoma

A carcinoma that arises from the colon or rectum and has metastasized to another anatomic site.


Metastatic Colon Carcinoma

A carcinoma that arises from the colon and has metastasized to another anatomic site.


Metastatic Rectal Carcinoma

A carcinoma that arises from the rectum and has metastasized to another anatomic site.


Metastatic Thyroid Gland Follicular Carcinoma

A follicular carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.


Metastatic Thyroid Gland Papillary Carcinoma

A papillary carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.


Metastatic Neuroblastoma

A neuroblastoma that has metastasized from its original site of growth to another anatomic site.


Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

The reemergence of a blastic plasmacytoid dendritic cell neoplasm after a period of remission.


Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic plasmacytoid dendritic cell neoplasm that is resistant to treatment.


Localized Gastroesophageal Junction Adenocarcinoma

An adenocarcinoma that arises from the gastroesophageal junction and has not spread to other anatomic sites.


Localized Gastric Carcinoma

A carcinoma that arises from the stomach and has not spread to other anatomic sites.


Refractory Aggressive Non-Hodgkin Lymphoma

An aggressive non-Hodgkin lymphoma that is resistant to treatment.


Locally Advanced Pancreatic Adenocarcinoma

A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Advanced Prostate Carcinoma

A prostatic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Prostate Carcinoma

A prostatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Advanced Prostate Adenocarcinoma

A prostatic adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


High Risk Acute Myeloid Leukemia

Acute myeloid leukemia characterized by poor response to induction chemotherapy and poor long-term survival following treatment with consolidation chemotherapy.


Advanced Cervical Carcinoma

A cervical carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Cervical Carcinoma

A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Unresectable Cervical Carcinoma

A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Advanced Cervical Adenocarcinoma

A cervical adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Peripheral neuropathy due to and following antineoplastic therapy

Any disorder affecting the peripheral nerves resulting from exposure to chemotherapeutic agents.


Recurrent Primary Peritoneal Serous Adenocarcinoma

The reemergence of primary peritoneal serous adenocarcinoma after a period of remission.


Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma

The reemergence of primary peritoneal low grade serous adenocarcinoma after a period of remission.


Recurrent Ovarian Low Grade Serous Adenocarcinoma

The reemergence of ovarian low-grade serous adenocarcinoma after a period of remission.


Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma

The reemergence of low grade fallopian tube serous adenocarcinoma after a period of remission.


Extrapulmonary Small Cell Carcinoma

A small cell neuroendocrine carcinoma that arises from an anatomic site other than the lung.


Succinate Dehydrogenase-Deficient Renal Cell Carcinoma

A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.


Refractory Kaposi Sarcoma

Kaposi sarcoma that is resistant to treatment.


Kaposi's sarcoma, metastatic

Kaposi sarcoma that has spread from its original site of growth to another anatomic site.


Advanced Kaposi Sarcoma

Kaposi sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Genitourinary Cancer

A primary or metastatic malignant neoplasm that affects the genitourinary system.


Metastatic Neuroendocrine Neoplasm

A neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.


Advanced Neuroendocrine Neoplasm

A neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Pancreatic neuroendocrine tumor metastatic

A neuroendocrine tumor that arises from the islet cells of the pancreas and has spread to another anatomic site.


Advanced Pancreatic Neuroendocrine Tumor

A pancreatic neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Digestive System Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from any part of the digestive system and has metastasized to another anatomic site.


Steroid-Refractory Pneumonitis

Pneumonitis that does not respond to corticosteroid therapy.


Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

The reemergence of T-cell/histiocyte-rich large B-cell lymphoma after a period of remission.


Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Histologic transformation of a marginal zone lymphoma to an aggressive diffuse large B-cell lymphoma.


Malignant Abdominal Neoplasm

A primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen.


Pelvic Cancer

A primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis.


Recurrent Acute Erythroid Leukemia

The reemergence of acute erythroid leukemia after a period of remission.


Advanced Digestive System Carcinoma

Digestive system carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic basal cell carcinoma

A carcinoma that arises from the basal cells and has metastasized to another anatomic site.


Locally Advanced Basal Cell Carcinoma

A basal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Biochemically Recurrent Prostate Carcinoma

Increasing prostate-specific antigen (PSA) following prostatectomy or radiation therapy in a patient with a history of localized prostate carcinoma. Signs of metastasis are absent using the currently available scanning technology.


Biliary Tract Carcinoma

A carcinoma arising from the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, or gallbladder.


Recurrent Biliary Tract Carcinoma

The reemergence of a carcinoma arising from any part of the biliary tract after a period of remission.


Pancreatic adenocarcinoma resectable

Pancreatic adenocarcinoma that is amenable to surgical resection.


Resectable Pancreatic Acinar Cell Carcinoma

Pancreatic acinar cell carcinoma that is amenable to surgical resection.


Intrahepatic cholangiocarcinoma that is amenable to surgical resection.


Perimenopausal

Describes the time in a woman's life as she approaches menopause. This is usually three to five years before menopause and is often marked by irregular menstrual periods and many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.


Hormone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for hormone receptors.


Refractory Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


Primary Vitreoretinal Non-Hodgkin Lymphoma

An uncommon and potentially fatal intraocular non-Hodgkin lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system non-Hodgkin lymphoma. The majority of cases are diffuse large B-cell lymphomas.


Recurrent Paraganglioma

The reemergence of paraganglioma after a period of remission.


Unresectable Paraganglioma

Paraganglioma that is not amenable to surgical resection.


Unresectable Adrenal Gland Pheochromocytoma

Adrenal gland pheochromocytoma that is not amenable to surgical resection.


Locally Advanced Adrenal Gland Pheochromocytoma

Adrenal gland pheochromocytoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Skin Squamous Cell Carcinoma

Skin squamous cell carcinoma that is not amenable to surgical resection.


Unresectable Basal Cell Carcinoma

Basal cell carcinoma that is not amenable to surgical resection.


Monoclonal Gammopathy of Renal Significance

A condition caused by a B-cell or plasma cell clone resulting in the deposition of the secreted monoclonal immunoglobulin, without evidence for overt lymphoma or myeloma. This category includes a wide spectrum of renal pathology and include such lesions as immunoglobulin-associated amyloidosis, the monoclonal immunoglobulin deposition diseases (MIDDs; light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), C3 glomerulopathy with monoclonal gammopathy, light chain proximal tubulopathy (Fanconi syndrome), and several others.


Borderline Resectable Pancreatic Ductal Adenocarcinoma

A pancreatic ductal adenocarcinoma term that refers to a continuum between resectable and locally advanced unresectable disease.


Metastatic Lung Non-Small Cell Squamous Carcinoma

A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Colorectal Carcinoma Metastatic in the Liver

A carcinoma that originates from the colorectal area and has spread to the liver.


Testosterone Less than 50 ng/dL

A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 50 ng/dL.


Mental Status Change

An alteration in the mental status of an individual.


Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder

The reemergence of monomorphic post-transplant lymphoproliferative disorder after a period of remission.


Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder

A monomorphic post-transplant lymphoproliferative disorder that does not respond to treatment.


Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder

The reemergence of polymorphic post-transplant lymphoproliferative disorder after a period of remission.


Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

A polymorphic post-transplant lymphoproliferative disorder that does not respond to treatment.


Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents

Castration-resistant prostate carcinoma which is refractory to second-generation androgen receptor axis-targeted agents, namely abiraterone and enzalutamide.


High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

A finding indicating the presence of a high risk bladder urothelial carcinoma that does not invade muscle.


Metastatic Lung Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the lung and has spread to another anatomic site.


Platinum-Resistant Fallopian Tube Carcinoma

Fallopian tube carcinoma that progresses between one and six months of completing platinum therapy.


Platinum-Resistant Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that progresses between one and six months of completing platinum therapy.


Metastatic cholangiocarcinoma

A cholangiocarcinoma that has metastasized to other anatomic sites.


Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma

Histologic transformation of an indolent chronic lymphocytic leukemia to an aggressive diffuse large B-cell lymphoma.


Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma

Histologic transformation of a small lymphocytic lymphoma to an aggressive diffuse large B-cell lymphoma.


Urothelial carcinoma recurrent

The reemergence of urothelial carcinoma after a period of remission.


Locally Advanced Urothelial Carcinoma

A urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic adenoid cystic carcinoma

An adenoid cystic carcinoma that has spread from the original site of growth to other anatomic sites.


Recurrent Adenoid Cystic Carcinoma

The reemergence of adenoid cystic carcinoma after a period of remission.


Mismatch Repair Proficient

A finding indicating that a sample has normal concentrations of unmutated mismatch repair proteins and is either microsatellite stable or has low microsatellite instability.


Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

T-cell/histiocyte-rich large B-cell lymphoma that is resistant to treatment.


Refractory Plasmablastic Lymphoma

Plasmablastic lymphoma that is resistant to treatment.


Refractory Lymphoproliferative Disorder

Lymphoproliferative disorder that is resistant to treatment.


Refractory T-Cell Prolymphocytic Leukemia

T-cell prolymphocytic leukemia that is resistant to treatment.


Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma

The reemergence of subcutaneous panniculitis-like T-cell lymphoma after a period of remission.


Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma

Subcutaneous panniculitis-like T-cell lymphoma that is resistant to treatment.


Refractory B-Cell Prolymphocytic Leukemia

B-cell prolymphocytic leukemia that is resistant to treatment.


Metastatic Bladder Squamous Cell Carcinoma

Bladder squamous cell carcinoma that has spread to another anatomical site.


Metastatic Bladder Plasmacytoid Urothelial Carcinoma

Bladder plasmacytoid urothelial carcinoma that has spread to another anatomic site.


Metastatic Bladder Lipid-Rich Urothelial Carcinoma

Bladder lipid-rich urothelial carcinoma that has spread to another anatomic site.


Metastatic Kidney Medullary Carcinoma

Kidney medullary carcinoma that has spread to another anatomical site.


Metastatic Sarcomatoid Renal Cell Carcinoma

Sarcomatoid renal cell carcinoma that has spread to another anatomical site.


Neuroendocrine carcinoma of the bladder

A malignant, high grade neuroendocrine neoplasm that arises from the bladder. This category includes small cell and large cell neuroendocrine carcinoma.


Metastatic Bladder Large Cell Neuroendocrine Carcinoma

Bladder large cell neuroendocrine carcinoma that has spread to another anatomical site.


Metastatic Bladder Small Cell Neuroendocrine Carcinoma

Bladder small cell neuroendocrine carcinoma that has spread to another anatomic site.


Metastatic Prostate Small Cell Neuroendocrine Carcinoma

Prostate small cell neuroendocrine carcinoma that has spread to another anatomic site.


Metastatic Bladder Sarcomatoid Urothelial Carcinoma

Bladder sarcomatoid urothelial carcinoma that has spread to another anatomical site.


Metastatic Bladder Micropapillary Urothelial Carcinoma

Bladder micropapillary urothelial carcinoma that has spread to another anatomic site.


Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma

Bladder clear cell (glycogen-rich) urothelial carcinoma that has spread to another anatomic site.


Metastatic Bladder Giant Cell Urothelial Carcinoma

Bladder giant cell urothelial carcinoma that has spread to another anatomic site.


Metastatic Malignant Genitourinary System Neoplasm

A malignant neoplasm that arises from the genitourinary system and has metastasized to other anatomic sites.


Non-Neoplastic Chronic Respiratory System Disorder

A non-neoplastic longstanding disorder of the respiratory system.


Iodine deficiency

A deficiency of iodine in the diet.


nutritional disorder

Any condition related to a disturbance between proper intake and utilization of nourishment.


Preterm Birth Complication

A complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation.


Pneumonia caused by respiratory syncytial virus

Pneumonia that is attributed to the respiratory syncytial virus.


NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

A finding indicating the presence of a NF1 mutation in a sample from a patient with malignant peripheral nerve sheath tumor.


Recurrent B-Cell Prolymphocytic Leukemia

The reemergence of a B-cell prolymphocytic leukemia after a period of remission.


Refractory Digestive System Neuroendocrine Neoplasm

A digestive system neuroendocrine neoplasm that is resistant to treatment.


Advanced Digestive System Neuroendocrine Neoplasm

A digestive system neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm

A digestive system neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Refractory Cholangiocarcinoma

Cholangiocarcinoma that is resistant to treatment.


Refractory WHO Grade 2 Glioma

WHO grade 2 glioma that is resistant to treatment.


Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

The reemergence of B-cell non-Hodgkin lymphoma transformed after a period of remission.


Refractory Transformed B-Cell Non-Hodgkin Lymphoma

An indolent B-cell non-Hodgkin lymphoma which has undergone histologic transformation to an aggressive B-cell non-Hodgkin lymphoma and has become resistant to treatment.


Recurrent Transformed Chronic Lymphocytic Leukemia

The reemergence of chronic lymphocytic leukemia transformed to aggressive diffuse large B-cell lymphoma (Richter's transformation) after a period of remission.


Refractory Transformed Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia which has undergone histologic transformation to an aggressive diffuse large B-cell lymphoma (Richter's transformation) and has become resistant to treatment.


Refractory Endometrial Serous Adenocarcinoma

Endometrial serous adenocarcinoma that is resistant to treatment.


Refractory Endometrial Mixed Cell Adenocarcinoma

Endometrial mixed cell adenocarcinoma that is resistant to treatment.


Refractory Endometrial Clear Cell Adenocarcinoma

Endometrial clear cell adenocarcinoma that is resistant to treatment.


Refractory Adrenal Gland Pheochromocytoma

A pheochromocytoma that does not respond to treatment.


Recurrent Desmoplastic Small Round Cell Tumor

The reemergence of desmoplastic small round cell tumor after a period of remission.


Refractory Desmoplastic Small Round Cell Tumor

Desmoplastic small round cell tumor that is resistant to treatment.


Adenocarcinoma endometrial recurrent

The reemergence of endometrioid adenocarcinoma after a period of remission.


Metastatic Salivary Gland Carcinoma

A salivary gland carcinoma that has metastasized to another anatomic site.


Locally Advanced Salivary Gland Carcinoma

A salivary gland carcinoma that has spread to nearby tissues or lymph nodes.


Platinum-Resistant Lung Small Cell Carcinoma

Lung small cell carcinoma that is resistant to platinum therapy.


Platinum-Sensitive Disease

A finding indicating that a cancer responds to platinum therapy initially, but it comes back after a certain period. For ovarian cancer, it refers to cancer relapse at least six months after the end of platinum therapy.


Platinum-Sensitive Lung Small Cell Carcinoma

Lung small cell carcinoma that is sensitive to platinum therapy.


Skin lesion

A localized pathological or traumatic structural change, damage, deformity, or discontinuity of skin.


Unresectable Urethral Urothelial Carcinoma

Urethral urothelial carcinoma that is not amenable to surgical resection.


Unresectable Bladder Urothelial Carcinoma

Bladder urothelial carcinoma that is not amenable to surgical resection.


Unresectable Ureter Urothelial Carcinoma

Ureter urothelial carcinoma that is not amenable to surgical resection.


Unresectable Renal Pelvis Urothelial Carcinoma

A renal pelvis urothelial carcinoma that is not amenable to surgical resection.


Ocular Graft Versus Host Disease

Graft versus host disease occurring in the eye.


Unresectable Breast Carcinoma

Breast carcinoma that is not amenable to surgical resection.


Iron deficiency

Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss.


Iron deficiency without anemia

Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss; occurring in the absence of anemia.


Metastatic Large Cell Neuroendocrine Carcinoma

A large cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.


Locally Advanced Large Cell Neuroendocrine Carcinoma

A large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic small cell carcinoma

A small cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.


Metastatic Prostate Neuroendocrine Carcinoma

A neuroendocrine carcinoma that arises from the prostate gland and has spread to other anatomic sites.


Metastatic Pancreatic Ductal Adenocarcinoma

An adenocarcinoma that arises from the exocrine pancreatic ducts and has metastasized to other anatomic sites.


Proliferative Glomerulonephritis with Monoclonal IgG Deposits

A sub-type of monoclonal gammopathy of renal significance, characterized by restriction to a single immunoglobulin G heavy chain subclass and a single light chain isotype. Light microscopy often shows an endocapillary proliferative or membranoproliferative glomerulopathy. Electron microscopy reveals electron-dense subendothelial and mesangial deposits.


Primary peritoneal carcinosarcoma

An extremely rare and highly aggressive malignant neoplasm arising from the peritoneum.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.


Liver Lesion

A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the liver.


Advanced Gastroesophageal Junction Adenocarcinoma

Gastroesophageal junction adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Adenocarcinoma

An adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Clear Cell Renal Cell Carcinoma

A clear cell renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Recurrent Adenocarcinoma

An adenocarcinoma that has recurred after a period of remission.


Bladder Melanoma

A rare melanoma that arises from the bladder mucosa.


Urethral Melanoma

A rare melanoma that arises from the urethral mucosa.


Advanced Endometrial Carcinoma

An endometrial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Epstein-Barr virus-associated malignant lymphoproliferative disorder

A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.


Unresectable Gastric Carcinoma

A gastric carcinoma that is not amenable to surgical resection.


Platinum-Sensitive Ovarian Carcinoma

Ovarian carcinoma that has a documented response to platinum-based chemotherapy.


Low Anterior Resection Syndrome

A collection of symptoms following removal of part or all of the rectum that may include frequency or urgency of stools, numerous bowel movements over a few hours, fecal incontinence, constipation alternating with numerous bowel movements, and/or increased intestinal gas.


High grade B-cell lymphoma recurrent

The reemergence of high-grade B-cell lymphoma after a period of remission.


Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

The reemergence of diffuse large B-cell lymphoma germinal center B-cell type after a period of remission.


Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

The reemergence of diffuse large B-cell lymphoma activated B-cell type after a period of remission.


Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

The reemergence of transformed follicular lymphoma to diffuse large B-cell lymphoma after a period of remission.


High grade B-cell lymphoma refractory

High-grade B-cell lymphoma that is resistant to treatment.


Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Diffuse large B-cell lymphoma germinal center B-cell type that is resistant to treatment.


Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Diffuse large B-cell lymphoma activated B-cell type that is resistant to treatment.


Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Transformed follicular lymphoma to diffuse large B-cell lymphoma that is resistant to treatment.


Unresectable Lung Small Cell Carcinoma

Lung small cell carcinoma that is not amenable to surgical resection.


Advanced Lung Small Cell Carcinoma

Small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic NUT Carcinoma

NUT carcinoma that has spread from its original site of growth to another anatomic site.


Advanced NUT Carcinoma

NUT carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Unresectable NUT Carcinoma

NUT carcinoma that is not amenable to surgical resection.


Executive dysfunction

Cognitive, emotional, and behavioral difficulties that often occur in conjunction with frontal lobe disorders, including traumatic injury and dementia. It is also a feature of attention deficit disorder and other non-trauma-induced conditions.


Advanced Esophageal Carcinoma

Esophageal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Lung Non-Small Cell Carcinoma

A non-small cell carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


Adenocarcinoma of colon metastatic

An adenocarcinoma that arises from the colon and has metastasized to another anatomic site.


Metastatic rectal adenocarcinoma

An adenocarcinoma that arises from the rectum and has metastasized to another anatomic site.


Advanced Paraganglioma

A paraganglioma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Adrenal Gland Pheochromocytoma

An adrenal gland pheochromocytoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Platinum-Sensitive Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that has a documented response to platinum-based chemotherapy.


Platinum-Sensitive Fallopian Tube Carcinoma

Fallopian tube carcinoma that has a documented response to platinum-based chemotherapy.


Recurrent Anaplastic Ependymoma

The reemergence of anaplastic ependymoma after a period of remission.


Locally Advanced Liposarcoma

A liposarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Leiomyosarcoma

A leiomyosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Undifferentiated Pleomorphic Sarcoma

An undifferentiated pleomorphic sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Breast Carcinoma

A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Sinonasal Adenocarcinoma

Adenocarcinomas that arises from the sinonasal tract. This category includes salivary-type and non-salivary type adenocarcinomas. The latter includes intestinal-type and non-intestinal-type adenocarcinomas.


Oligometastatic malignant neoplasm

A finding of a malignant solid neoplasm that has metastasized to a limited number of sites-existing in a state intermediate between localized disease and widespread metastatic disease.


Metastatic Colorectal Adenocarcinoma

Colorectal adenocarcinoma that has spread from the original site of growth to other anatomic sites.


Estrogen Receptor Status

The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a "late-onset" form of breast cancer and for an older woman to have an "early-onset" variant of the disease.


Metastatic Clear Cell Sarcoma of Soft Tissue

A clear cell sarcoma of soft tissue that has spread from the original site of growth to other anatomic sites.


Double-Negative Prostate Carcinoma

A metastatic, castration-resistant prostate carcinoma that is composed of fibroblast growth factor-driven malignant cells.


Metastatic BRCA-Associated Breast Carcinoma

BRCA-associated breast carcinoma that has spread to another anatomic site.


Hepatocellular Malignant Neoplasm, Not Otherwise Specified

A rare childhood malignant liver neoplasm with overlapping features of hepatoblastoma and hepatocellular carcinoma.


Refractory Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma that is resistant to treatment.


Unresectable Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma that is not amenable to surgical resection.


Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma

Gastroesophageal junction adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Unresectable Colon Adenocarcinoma

A colon adenocarcinoma that is not amenable to surgical resection.


Unresectable Rectal Adenocarcinoma

A rectal adenocarcinoma that is not amenable to surgical resection.


Advanced Colon Adenocarcinoma

Colon adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Refractory Colorectal Adenocarcinoma

Colorectal adenocarcinoma that is resistant to treatment.


Refractory Rectal Carcinoma

Rectal carcinoma that is resistant to treatment.


Advanced Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Unresectable Breast Carcinoma

A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Advanced Soft Tissue Sarcoma

A sarcoma of soft tissue that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IB3 Cervical Cancer FIGO 2018

Invasive cervical carcinoma equal or more than 4 cm in greatest dimension. (FIGO 2018)


Stage II Cervical Cancer FIGO 2018

The cervical carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall. (FIGO 2018)


Stage IIA Cervical Cancer FIGO 2018

Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement. (FIGO 2018)


Stage IIA1 Cervical Cancer FIGO 2018

Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension. (FIGO 2018)


Stage IIA2 Cervical Cancer FIGO 2018

Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension. (FIGO 2018)


Stage IIB Cervical Cancer FIGO 2018

Cervical carcinoma with parametrial involvement but not up to the pelvic wall. (FIGO 2018)


Stage III Cervical Cancer FIGO 2018

Cervical carcinoma that involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney and/or involves pelvic and/or para-aortic lymph nodes. (FIGO 2018)


Stage IIIA Cervical Cancer FIGO 2018

Cervical carcinoma that involves the lower third of the vagina, with no extension to the pelvic wall. (FIGO 2018)


Stage IIIB Cervical Cancer FIGO 2018

Cervical carcinoma with extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause). (FIGO 2018)


Stage IIIC Cervical Cancer FIGO 2018

Cervical carcinoma with involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent (with r and p notations). (FIGO 2018)


Stage IIIC1 Cervical Cancer FIGO 2018

Cervical carcinoma with pelvic lymph node metastasis only. (FIGO 2018)


Stage IIIC2 Cervical Cancer FIGO 2018

Cervical carcinoma with para-aortic lymph node metastasis. (FIGO 2018)


Stage IVA Cervical Cancer FIGO 2018

The cervical carcinoma has spread to adjacent pelvic organs. (FIGO 2018)


Metastatic Malignant Female Reproductive System Neoplasm

A malignant neoplasm that arises in the female reproductive system and has spread from its original site of growth to other anatomic sites.


Metastatic Malignant Digestive System Neoplasm

A malignant neoplasm that arises in the digestive system and has spread from its original site of growth to other anatomic sites.


Resectable Colorectal Carcinoma

Colorectal carcinoma that is amenable to surgical resection.


Locally Advanced Unresectable Colorectal Adenocarcinoma

A colorectal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Metastatic Appendix Carcinoma

Carcinoma of the appendix that has spread from the original site of growth to other anatomic sites.


EBV-Related Sarcoma

Sarcoma that is caused by Epstein-Barr virus infection.


EBV-Related Leiomyosarcoma

Leiomyosarcoma that is caused by Epstein-Barr virus infection.


Recurrent Colorectal Adenocarcinoma

The reemergence of colorectal adenocarcinoma after a period of remission.


Adenocarcinoma of colon recurrent

The reemergence of colon adenocarcinoma after a period of remission.


Rectal adenocarcinoma recurrent

The reemergence of rectal adenocarcinoma after a period of remission.


Refractory Hepatocellular Carcinoma

Hepatocellular carcinoma that is resistant to treatment.


Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

The reemergence of high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements after a period of remission.


Refractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

High-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements that is resistant to treatment.


Intermediate Risk Acute Myeloid Leukemia

Acute myeloid leukemia with a risk of relapse or refractoriness between favorable and high risk acute myeloid leukemia, and cytogenetic and molecular genetic abnormalities that categorize it as intermediate risk acute myeloid leukemia.


Metastatic Thymic Neuroendocrine Neoplasm

A thymic neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.


Advanced Colorectal Carcinoma

Colorectal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Refractory Gastroesophageal Junction Adenocarcinoma

Gastroesophageal junction adenocarcinoma that does not respond to treatment.


Primary Peritoneal Undifferentiated Carcinoma

An extremely rare carcinoma arising from the peritoneum. It is characterized by the presence of a diffuse malignant infiltrate that is composed of epithelial cells without evidence of glandular or squamous differentiation.


Primary Peritoneal Transitional Cell Carcinoma

An extremely rare transitional cell carcinoma that arises from the peritoneum.


Clear cell adenocarcinoma of peritoneum

An extremely rare adenocarcinoma arising from the peritoneum. It is composed of malignant glandular epithelium containing clear cells.


Metastatic Merkel Cell Carcinoma

A Merkel cell carcinoma that has spread from the original site of growth to another anatomic site.


Metastatic Malignant Neoplasm in the Head and Neck

The spread of a malignant neoplasm to the head and neck.  This may be from a primary head and neck malignant neoplasm, or from a malignant neoplasm at a distant site.


Head and Neck Carcinoma of Unknown Primary

A carcinoma that has metastasized to the head and neck region from an unknown primary anatomic site. Metastatic squamous cell carcinoma in the neck lymph nodes accounts for the vast majority of these lesions.


Unresectable Colorectal Carcinoma

A colorectal carcinoma that is not amenable to surgical resection.


Unresectable Fibrolamellar Carcinoma

A fibrolamellar carcinoma that is not amenable to surgical resection.


The reemergence of adamantinomatous craniopharyngioma after a period of remission.


Locally Advanced Ureter Urothelial Carcinoma

A ureter urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Renal Pelvis Urothelial Carcinoma

A renal pelvis urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Bladder Urothelial Carcinoma

A bladder urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Locally Advanced Urethral Urothelial Carcinoma

A urethral urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Squamous Cell Carcinoma

Squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Resectable Osteosarcoma

Osteosarcoma that is amenable to surgical resection.


Metastatic Thyroid Gland Medullary Carcinoma

A thyroid gland medullary carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Chordoma

A chordoma that does not respond to treatment.


Refractory Epithelioid Sarcoma

An epithelioid sarcoma that does not respond to treatment.


Refractory Atypical Teratoid/Rhabdoid Tumor

An atypical teratoid/rhabdoid tumor that does not respond to treatment.


Recurrent Kidney Medullary Carcinoma

The reemergence of kidney medullary carcinoma after a period of remission.


Refractory Kidney Medullary Carcinoma

A kidney medullary carcinoma that does not respond to treatment.


Recurrent Rhabdoid Tumor of the Kidney

The reemergence of a rhabdoid tumor of the kidney after a period of remission.


Refractory Rhabdoid Tumor of the Kidney

A rhabdoid tumor of the kidney that does not respond to treatment.


Refractory Biliary Tract Carcinoma

Biliary tract carcinoma that is resistant to treatment.


Advanced Cholangiocarcinoma

A cholangiocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Refractory Gallbladder Carcinoma

Gallbladder carcinoma that is resistant to treatment.


Metastatic Gallbladder Carcinoma

A gallbladder carcinoma that has spread from the original site of growth to other anatomic sites.


Advanced Gallbladder Carcinoma

Gallbladder carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Cancer-related Cognitive Dysfunction

The effects of cancer and its treatments on cognitive processes.


Locally Advanced Head and Neck Squamous Cell Carcinoma

A head and neck squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.